CNTB Relative Valuation
CNTB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNTB is overvalued; if below, it's undervalued.
Historical Valuation
Connect Biopharma Holdings Ltd (CNTB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.51. The fair price of Connect Biopharma Holdings Ltd (CNTB) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：2.57
Fair
-1.98
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Connect Biopharma Holdings Ltd. (CNTB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.46. The thresholds are as follows: Strongly Undervalued below -15.59, Undervalued between -15.59 and -9.02, Fairly Valued between 4.11 and -9.02, Overvalued between 4.11 and 10.68, and Strongly Overvalued above 10.68. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.26
EV/EBIT
Connect Biopharma Holdings Ltd. (CNTB) has a current EV/EBIT of -1.26. The 5-year average EV/EBIT is -0.17. The thresholds are as follows: Strongly Undervalued below -8.21, Undervalued between -8.21 and -4.19, Fairly Valued between 3.86 and -4.19, Overvalued between 3.86 and 7.88, and Strongly Overvalued above 7.88. The current Forward EV/EBIT of -1.26 falls within the Historic Trend Line -Fairly Valued range.
49128.97
PS
Connect Biopharma Holdings Ltd. (CNTB) has a current PS of 49128.97. The 5-year average PS is 1346.66. The thresholds are as follows: Strongly Undervalued below -12716.61, Undervalued between -12716.61 and -5684.97, Fairly Valued between 8378.29 and -5684.97, Overvalued between 8378.29 and 15409.93, and Strongly Overvalued above 15409.93. The current Forward PS of 49128.97 falls within the Strongly Overvalued range.
-3.16
P/OCF
Connect Biopharma Holdings Ltd. (CNTB) has a current P/OCF of -3.16. The 5-year average P/OCF is -0.57. The thresholds are as follows: Strongly Undervalued below -4.19, Undervalued between -4.19 and -2.38, Fairly Valued between 1.23 and -2.38, Overvalued between 1.23 and 3.04, and Strongly Overvalued above 3.04. The current Forward P/OCF of -3.16 falls within the Undervalued range.
0.00
P/FCF
Connect Biopharma Holdings Ltd. (CNTB) has a current P/FCF of 0.00. The 5-year average P/FCF is -1.41. The thresholds are as follows: Strongly Undervalued below -10.57, Undervalued between -10.57 and -5.99, Fairly Valued between 3.17 and -5.99, Overvalued between 3.17 and 7.75, and Strongly Overvalued above 7.75. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Connect Biopharma Holdings Ltd (CNTB) has a current Price-to-Book (P/B) ratio of 2.67. Compared to its 3-year average P/B ratio of 0.71 , the current P/B ratio is approximately 277.66% higher. Relative to its 5-year average P/B ratio of 1.00, the current P/B ratio is about 166.20% higher. Connect Biopharma Holdings Ltd (CNTB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -90.38%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -86.48% , the current FCF yield is about -100.00% lower.
2.56
P/B
Median3y
0.71
Median5y
1.00
-29.03
FCF Yield
Median3y
-90.38
Median5y
-86.48
Competitors Valuation Multiple
The average P/S ratio for CNTB's competitors is 1.29, providing a benchmark for relative valuation. Connect Biopharma Holdings Ltd Corp (CNTB) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -98.69%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CNTB increased by 84.06% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.06K to -107.50K.
The secondary factor is the Revenue Growth, contributed -98.69%to the performance.
Overall, the performance of CNTB in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Connect Biopharma Holdings Ltd (CNTB) currently overvalued or undervalued?
What is Connect Biopharma Holdings Ltd (CNTB) fair value?
How does CNTB's valuation metrics compare to the industry average?
What is the current P/B ratio for Connect Biopharma Holdings Ltd (CNTB) as of Dec 05 2025?
What is the current FCF Yield for Connect Biopharma Holdings Ltd (CNTB) as of Dec 05 2025?
What is the current Forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB) as of Dec 05 2025?